Ancora Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Ancora Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.92K	Hold	100	–	–	﹤0.01%	1839
2025 Q4	$8.21K	Hold	100	–	–	﹤0.01%	1842
2025 Q3	$6.99K	Buy	+100	New	+$6.76K	﹤0.01%	1449
2018 Q4	–	Sell	-1,050	Closed	-$62K	–	1027
2018 Q3	$62K	Buy	+1,050	New	+$61.3K	﹤0.01%	847
2017 Q1	–	Sell	-1,050	Closed	-$41K	–	954
2016 Q4	$41K	Buy	+1,050	New	+$42.4K	﹤0.01%	810

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Ancora Advisors's PBE Position: Q1 2026 in Review

Ancora Advisors held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 100 shares worth $7.92K. The position accounts for ﹤0.01% of the portfolio, ranked #1839.

Ancora Advisors first reported a position in PBE in Q4 2016 and has held it in 5 quarters since. The position peaked at $62K in Q3 2018. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

Ancora Advisors held 100 shares of Invesco Biotechnology & Genome ETF worth $7.92K as of Q1 2026.
Ancora Advisors left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #1839 holding.
Ancora Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2016 and has held it in 5 quarters since.
Ancora Advisors's Invesco Biotechnology & Genome ETF position peaked at $62K in Q3 2018.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.